Uncategorized

Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop

Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.

Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop Read More »

Scroll to Top